Syntaxin will help in the discovery of new therapeutic candidates and Ipsen will aid in pharmacological, preclinical and clinical assessments of the newly discovered compounds.
As per the deal, Syntaxin will receive technology access fee, full time employee support, and research milestones amounting up to $9m in the first three years of the collaboration, besides being eligible to receive over $90m of commercial milestones together with royalties on net sales.
Ipsen in return will hold worldwide development and commercialisation rights to the programmes developed as part of the collaboration.